Volume 34, Issue 1, March 2023

Sign in to download the Issue in PDF format.

Mediterr J Rheumatol 2023;34(1):53-60
Clinical Manifestations of Behcet's Disease: A Retrospective Cross-Sectional Study
Authors Information
  1. Department of Internal Medicine, Vali-e-Asr Hospital, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
  2. Social Determinants of Health Research Centre, Zanjan University of Medical Sciences, Zanjan, Iran
  3. Behçet's Disease Unit, Rheumatology Research Centre, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
  4. Department of Ophthalmology, School of Medicine, Vali-E-Asr Hospital, Zanjan University of Medical sciences, Zanjan, Iran
  5. Department of Radiation Oncology, Vali-e-Asr Hospital, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
  6. Department of Emergency Medicine, Valiasr-e-Asr Hospital, Ayatollah Mousavi Hospital, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran

A Zeraatchi


Introduction: Behçet’s Disease (BD) is a systemic vasculitis, highly prevalent in Eastern Asia to Mediterranean countries. Iran is among the countries with the highest prevalence of BD, and previous studies in different countries have shown a broad range of clinical manifestations of the disease. The present study is conducted to evaluate the prevalence of the clinical manifestations of BD in patients referring to rheumatology clinics of two distinct referral hospitals in Tehran and Zanjan, Iran. Methods: In this retrospective, cross-sectional study, the medical records of patients with BD were reviewed, and age at onset, sex, the delay between the onset of symptoms and diagnosis, clinical manifestations, HLA B27, HLA B51, HLA B5, haematuria, proteinuria, leukocyturia, Erythrocyte Sedimentation Rate (ESR), and pathergy phenomenon were included in the study. The collected data were analysed by χ2 test using SPSS 23. Results: A total of 188 patients (Male/female ratio = 1.47) were included in the study with mean ± SD age at onset of 27.98 ± 10.47 years and a mean ± SD of delay between the onset of symptom and diagnosis of 5.70 ± 7.16 years. The most common clinical manifestation was mucosal involvement (85.1%), followed by the ocular lesion (55.3%) and skin manifestations (44.7%). The Pathergy phenomenon was observed in 98 patients (52.1%). Moreover, 45.2% had positive HLA B5, followed by HLA B51 (35.1%) and HLA B27 (12.2%). Conclusion: This study demonstrated thatmale/female ratio and mean age at onset were comparable to the results of previous studies in Iran. Significant associations between HLAB5 and clinical manifestations underline the pivotal role of genetic factors in BD.

Cite this article as: Sadeghi A, Rostami M, Amraei G, Davatchi F, Shahram F, Karimi Μoghaddam A, Karimi Μoghaddam Z, Zeraatchi A. Clinical Manifestations of Behçet’s Disease: A Retrospective Cross-Sectional Study. Mediterr J Rheumatol 2023;34(1):53-60.

Article Submitted: 5 Nov 2011; Revised Form: 23 Nov 2022; Article Accepted: 15 Dec 2022; Available Online: 31 Mar 2023


This work is licensed under a Creative Commons Attribution 4.0 International License.

©2022 The Author(s).